Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.20.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets    
Cash and cash equivalents $ 72,256 $ 8,604
Restricted cash 154 89
Short-term deposits 10,003 31,055
Related parties 50
Other current assets 2,068 140
Total current assets 84,531 39,888
Non-current assets    
Lease deposit 5
Operating lease right-of-use asset 1,148
Property and equipment, net 1,881 887
In-process research and development (“R&D”) 4,556 4,556
Total non-current assets 7,590 5,443
Total asset 92,121 45,331
Current liabilities    
Trade account payables 3,253 193
Current portion of lease liabilities 375
Other account payables 2,596 1,396
Related parties 50
Total current liabilities 6,224 1,639
Non-current liabilities    
Lease liabilities – net of current portion 856
Contingent liabilities 585 889
Total non-current liabilities 1,441 889
Commitments and Contingent Liabilities
Shareholders’ equity    
Common stock shares, $0.0001 par value ("Ordinary Shares"); Authorized 60,000,000 and 33,954,304 shares as of December 31, 2019 and 2018, respectively. Issued and outstanding 22,862,835 and 2,307,871 as of December 31, 2019 and 2018, respectively. 2 [1]
Preferred A shares (pre-merger - BiomX Ltd.) ("Preferred A Shares"); NIS 0.01 par value; Authorized 16,430,668 shares as of December 31, 2018. Issued and outstanding 7,543,831 shares as of December 31, 2018. 1
Preferred B shares (pre-merger - BiomX Ltd.) ("Preferred B Shares"); NIS 0.01 par value; Authorized 6,858,371 shares as of December 31, 2018. Issued and outstanding 5,170,357 shares as of December 31, 2018. 1
Additional paid in capital 126,626 64,410
Accumulated deficit (42,172) (21,609)
Total shareholders' equity 84,456 42,803
Total liabilities and shareholders' equity $ 92,121 $ 45,331
[1] Less than $1 thousand.